JAVELIN Bladder 100: Avelumab maintenance for metastatic or locally advanced bladder cancer скачать в хорошем качестве

JAVELIN Bladder 100: Avelumab maintenance for metastatic or locally advanced bladder cancer

Joaquim Bellmunt, MD, PhD, Harvard Medical School and Dana-Farber Cancer Institute, Boston, MA, discusses the JAVELIN Bladder 100 study (NCT02603432), which investigated avelumab maintenance therapy for patients with metastatic or locally advanced bladder cancer. Patients who did not progress after receiving 4-6 cycles of first-line cisplatin-based chemotherapy were randomised to receive either avelumab maintenance plus best supportive care vs best supportive care alone, with a primary endpoint of overall survival. Results published in 2020 showed a significant survival benefit for avelumab maintenance therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.